Clinical Trials Logo

Deglutition Disorders clinical trials

View clinical trials related to Deglutition Disorders.

Filter by:

NCT ID: NCT03577444 Not yet recruiting - Stroke Clinical Trials

Role of Genetic Polymorphism in Neuroplasticity Involved in Dysphagia Recovery

Start date: July 1, 2018
Phase:
Study type: Observational

The purpose of this study is to assess the association of genetic polymorphism such as the Brain-derived Neurotrophic factor (BDNF), in neurogenic dysphagia in those with brain lesion.

NCT ID: NCT03562104 Not yet recruiting - Clinical trials for Traumatic Brain Injury

Swallowing Disorders in Minimally Consciousness Patients (MCS)

TC-DEG
Start date: September 1, 2018
Phase: N/A
Study type: Interventional

This study aimed to characterize swallowing disorders in minimally consciousness patients after brain traumatic injury.

NCT ID: NCT03552185 Recruiting - Multiple Sclerosis Clinical Trials

Depicting Neurogenic Dysphagia in Multiple Sclerosis Patients; Clinical and Endoscopic Studies

Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to evaluate neurogenic dysphagia in Multiple Sclerosis patients using dysphagia questionnaires and endoscopic study; and to correlate that to MS types, severity, duration, and imaging modalities

NCT ID: NCT03540953 Terminated - Clinical trials for Head and Neck Neoplasms

Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis

Start date: January 5, 2015
Phase: N/A
Study type: Interventional

Management of pharyngoesophageal stenosis (PES) in patients after head and neck cancer (HNC) treatment remains a challenge. There are some cases of strictures refractory to dilation sessions. This study aimed to evaluate the efficacy of Mitomycin C (MMC) endoscopic injection for the treatment of refractory pharyngoesophageal stenosis. Patients and methods: This is a prospective study in patients with dysphagia following head and neck cancer treatment, without evidence suggestive of tumor recurrence, and refractory to endoscopic treatment. Theses undergo endoscopic dilation of the stenotic segment with thermoplastic bougies, followed by the injection of MMC.

NCT ID: NCT03524703 Recruiting - Dysphagia Clinical Trials

Short-term Effect of Chewing Gum in Patients With Mild-moderate Dysphagia After Anterior Cervical Fusion

Start date: April 28, 2018
Phase: N/A
Study type: Interventional

The aim of the study is to estimate the effect of chewing gum after anterior cervical fusion surgery on decreasing the severity of dysphagia in patients with mild-moderate dysphagia.

NCT ID: NCT03513393 Not yet recruiting - Hepatitis C Clinical Trials

Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole.

COPA
Start date: August 1, 2018
Phase: Phase 1
Study type: Interventional

Epclusa® is a pan-genotypic, once-daily tablet for the treatment of chronic hepatitis C virus (HCV) infection containing the NS5B- polymerase inhibitor sofosbuvir (SOF, nucleotide analogue) 400 mg and the NS5A inhibitor velpatasvir (VEL) 100 mg. Velpatasvir has pH dependent absorption. At higher pH the solubility of velpatasvir decreases. It has been shown that in subjects treated with proton pump inhibitors (PPIs) such as omeprazole, the absorption of velpatasvir is reduced by 26-56%, depending on the dose of omeprazole, concomitant food intake, and timing/sequence of velpatasvir vs. omeprazole intake. As a result, concomitant intake of PPIs with velpatasvir is not recommended. For a number of reasons, the prohibition of PPI use with velpatasvir is a clinically relevant problem. First, PPI use is highly frequent in the HCV-infected subject population with prevalences reported up to 40%. Second, PPIs are available as over-the-counter medications and thus can be used by subjects without informing their physician. Third, although HCV therapy is generally well tolerated, gastro-intestinal symptoms such as abdominal pain and nausea are frequently reported, which my lead to PPI use. One solution of this problem could be the use of other acid-reducing agents such as H2-receptor antagonists or antacids. In general, they have a less pronounced effect on intragastric pH, and are considered less effective than PPIs by many patients and physicians. A second solution would be the choice of another HCV agent or combination that is not dependent on low gastric pH for its absorption such as daclatasvir. Daclatasvir, however, is not a pan-genotypic HCV agent and may be less effective against GT 2 and 3 infections than velpatasvir. Second, not all subjects have access to daclatasvir, depending on health insurance company or region where they live. A third solution, and the focus of this COPA study, is to add a glass of the acidic beverage cola at the time of velpatasvir administration in subjects concurrently treated with PPIs. This intervention has been shown to be effective for a number of drugs from other therapeutic classes who all have in common a reduced solubility (and thus reduced absorption) at higher intragastric pH, namely erlotinib, itraconazole, ketoconazole. The advantages of this approach are: (1) only a temporary decrease in gastric pH at the time of cola intake; the rest of the day the PPI will have its therapeutic effect (2) cola is available worldwide (3) the administration of cola can be done irrespective to the timing of PPI use.

NCT ID: NCT03499574 Recruiting - Stroke, Acute Clinical Trials

Feasibility Study of Biofeedback in Dysphagia Therapy Post Stroke

Start date: January 26, 2018
Phase: N/A
Study type: Interventional

This study will investigate the feasibility of delivering swallowing therapy using surface electromyography as a means of biofeedback to patients with dysphagia in the acute stroke setting. It will investigate trends in efficacy by comparing biofeedback therapy to usual care. The results will inform future dosing and efficacy studies.

NCT ID: NCT03494361 Completed - Clinical trials for Deglutition Disorders

Evaluation of Dysphagia by 6-chnnel Surface Electromyography

Start date: July 4, 2016
Phase:
Study type: Observational

The natural process of aging affects a few very specific timing parameters such as swallow reaction time and hyoid one movement velocity. Many swallow timing and bolus transit parameters appear to be unaffected by aging. We want to know the changes of kinematic variables according to the aging process. First hypothesis: There are probably be a protection mechanism that blocks functional loss progressing to kinematic abnormality. Muscle activation sequence change (i.e duration or amplitude) of the oropharyngeal muscles play an important role. Second hypothesis: Age-related differences in muscle activation patterns will also appear differently depending on the characteristics of swallowed food.

NCT ID: NCT03488147 Not yet recruiting - Dysphagia Clinical Trials

Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery

Start date: April 2, 2018
Phase: Phase 2
Study type: Interventional

The researchers wish to investigate whether proton pump inhibitors, administered prior to or after surgery, can reduce the incidence and/or severity of difficulty swallowing foods and/or liquids,following anterior cervical surgery.

NCT ID: NCT03487510 Completed - Clinical trials for Deglutition Disorders

Dysphagia on the Intensive Care Unit

DICE-SWISS
Start date: November 11, 2017
Phase:
Study type: Observational

Recording of routine practice patterns to detect and/or treat Dysphagia on the ICU via interview of local colleagues. This will not allow to record generalizable data, but will reflect the actual routine standard of care.